Lilly rides wave of weight-loss drug demand, working to expand capacity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Eli Lilly (LLY) beats profit forecast amid soaring weight-loss drug demand
February 6, 2024 6:58 AM EST(Updated - February 6, 2024 8:26 AM EST)
Investing.com -- Eli Lilly (NYSE: LLY) has reported fourth-quarter revenue that topped estimates thanks in large part to soaring demand for its weekly diabetes injection.
The U.S. drugmaker's treatment -- branded as Mounjaro -- is in a race with a rival version from Denmark's Novo Nordisk to... More
